Article
Can CD147 work as a therapeutic target for tumors through COVID-19 infection?
1 Jan 2022
Abstract excerpt
In this review, we discussed an interesting case infected with "COVID-19" (Corona Virus Disease 2019). The patients with Hodgkin's lymphoma recovered after infection with COVID-19. It may be that COVID-19 activates the patient's immune system, or it may be a coincidence. COVID-19 spike protein can interact with CD147 and use it as an entry to invade host cells. CD147 is a partner of SLC3A2, which is the chaperone...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
